ArticleBioinformation2024
Gene expression analysis of Schizophrenia.
Article in Bioinformation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Schizophrenia as a Disorder of Biological Barriers: A Narrative Review and Potential Interventions.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia is a chronic psychiatric disorder marked by cognitive deficits associated with prefrontal cortical dysfunction, particularly in Broadmann Area 10 (BA 10), where gray matter reduction is observed. The genetic mechanisms behind these abnormalities remain unclear. Therefore, it is of interest to analyze altered gene expression and pathways in the prefrontal cortex of schizophrenia patients. We used two GEO datasets - GSE12654 (discovery) and GSE17612 (validation) and differential gene expression was assessed between schizophrenia patients and healthy controls. Validation confirmed three upregulated genes (S100A9, S100A8, BCL2A1) and one downregulated gene (CBLB), with protein interaction analysis revealing that upregulated genes were linked to immune and apoptotic processes, while downregulated genes suppressed EGF pathways. These findings suggest immune dysfunction and gray matter loss in schizophrenia, highlighting potential biomarkers and therapeutic targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.